AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.

Guideline ID: 2995 Published: 2023 Feb 1

American Association for the Study of Liver Diseases (AASLD)

Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702. [505 references] PubMed

View Original Guideline

Overview

Guideline Objective

To provide guidance on diagnosis and management of primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA)

Patient Population

Patients with suspected or confirmed PSC and/or CCA

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Diagnostic considerations for PSC, including magnetic resonance imaging (MRI) with and without cholangiopancreatography, biopsy, and ileocolonoscopy
- Risk stratification and fibrosis staging, including longitudinal section (LS) measurement by transient elastography (TE) or magnetic resonance elastography (MRE)
- Management considerations for PSC, including medical management, surveillance for malignancy, endoscopic and percutaneous therapy, symptom management, and nutritional and bone assessment
- Diagnosis and management of intrahepatic CCA (iCCA) and of perihilar and distal CCA

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Supporting Statement from American Association for the Study of Liver Diseases (AASLD): Regarding the New AASLD Guidance for Primary Sclerosing Cholangitis (PSC) and Cholangiocarcinoma; 2022 Sep 9.
- PSC Partners Comment on the Newly Published AASLD Guidance for Primary Sclerosing Cholangitis (PSC) and Cholangiocarcinoma: Recommendation about the use of Oral Vancomycin in PSC; 2022 Sep 11.

- AASLD Policy on Development and Use of Practice Guidelines, Guidances, and Position Papers.

Implementation Tools

- Liver*Learning*® website.

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2025 ECRI